Pay in 4 interest-free payments of $5.21 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
The Endocrine Society notes that medications used for weight management should be part of a broader plan that includes diet, exercise, and behavioral modification
Prescribing GLP-1s for obesityor any chronic disorderdoesnt obviate the need for lifestyle changes, which are paramount to decreasing inflammation and the risk of developing CIDs
Diabetic retinopathy, caused by prolonged high blood sugar damaging retinal blood vessels, affects over 90% of individuals with type 1 diabetes and 5060% of those with type 2 diabetes
doi:10.1080/14740338.2024.2419989 115
Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes
That mix of motivations matters for insurers because public drug plans generally only cover GLP1s for type 2 diabetes, leaving most obesityfocused use in the private market, the survey said
